Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 1
2017 1
2018 3
2019 3
2021 2
2022 10
2023 3
2024 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

24 results

Results by year

Filters applied: . Clear all
Page 1
Trial of Anti-BDCA2 Antibody Litifilimab for Cutaneous Lupus Erythematosus.
Werth VP, Furie RA, Romero-Diaz J, Navarra S, Kalunian K, van Vollenhoven RF, Nyberg F, Kaffenberger BH, Sheikh SZ, Radunovic G, Huang X, Clark G, Carroll H, Naik H, Gaudreault F, Meyers A, Barbey C, Musselli C, Franchimont N; LILAC Trial Investigators. Werth VP, et al. N Engl J Med. 2022 Jul 28;387(4):321-331. doi: 10.1056/NEJMoa2118024. N Engl J Med. 2022. PMID: 35939578 Clinical Trial.
Trial of Anti-BDCA2 Antibody Litifilimab for Systemic Lupus Erythematosus.
Furie RA, van Vollenhoven RF, Kalunian K, Navarra S, Romero-Diaz J, Werth VP, Huang X, Clark G, Carroll H, Meyers A, Musselli C, Barbey C, Franchimont N; LILAC Trial Investigators. Furie RA, et al. N Engl J Med. 2022 Sep 8;387(10):894-904. doi: 10.1056/NEJMoa2118025. N Engl J Med. 2022. PMID: 36069871 Clinical Trial.
IFN-γ ELISpot-enabled machine learning for culprit drug identification in nonimmediate drug hypersensitivity.
Chongpison Y, Sriswasdi S, Buranapraditkun S, Thantiworasit P, Rerknimitr P, Mongkolpathumrat P, Chularojanamontri L, Srinoulprasert Y, Rerkpattanapipat T, Chanprapaph K, Disphanurat W, Chakkavittumrong P, Tovanabutra N, Srisuttiyakorn C, Sukasem C, Tuchinda P, Pongcharoen P, Klaewsongkram J. Chongpison Y, et al. Among authors: chakkavittumrong p. J Allergy Clin Immunol. 2024 Jan;153(1):193-202. doi: 10.1016/j.jaci.2023.08.026. Epub 2023 Sep 9. J Allergy Clin Immunol. 2024. PMID: 37678574
Cutaneous Adverse Events After COVID-19 Vaccination.
Weschawalit S, Pongcharoen P, Suthiwartnarueput W, Srivilaithon W, Daorattanachai K, Jongrak P, Chakkavittumrong P. Weschawalit S, et al. Among authors: chakkavittumrong p. Clin Cosmet Investig Dermatol. 2023 Jun 8;16:1473-1484. doi: 10.2147/CCID.S410690. eCollection 2023. Clin Cosmet Investig Dermatol. 2023. PMID: 37313511 Free PMC article.
Topical cannabidiol-based treatment for psoriasis: A dual-centre randomized placebo-controlled study.
Puaratanaarunkon T, Sittisaksomjai S, Sivapornpan N, Pongcharoen P, Chakkavittumrong P, Ingkaninan K, Temkitthawon P, Promgool T, Waranuch N, Asawanonda P. Puaratanaarunkon T, et al. Among authors: chakkavittumrong p. J Eur Acad Dermatol Venereol. 2022 Sep;36(9):e718-e720. doi: 10.1111/jdv.18215. Epub 2022 May 16. J Eur Acad Dermatol Venereol. 2022. PMID: 35536599 Clinical Trial. No abstract available.
Effects of some medicinal plant extracts on dermal papilla cells.
Wisuitiprot V, Ingkaninan K, Wisuitiprot W, Srivilai J, Chakkavittumrong P, Waranuch N. Wisuitiprot V, et al. Among authors: chakkavittumrong p. J Cosmet Dermatol. 2022 Nov;21(11):6109-6117. doi: 10.1111/jocd.15148. Epub 2022 Jul 19. J Cosmet Dermatol. 2022. PMID: 35675125
24 results